Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 17;12(20):6573.
doi: 10.3390/jcm12206573.

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

Michał Adamczyk  1 , Joanna Bartosińska  1   2 , Dorota Raczkiewicz  3 , Małgorzata Kowal  1 , Agata Surdacka  4 , Danuta Krasowska  5 , Anna Michalak-Stoma  1 , Dorota Krasowska  1
Affiliations

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

Michał Adamczyk et al. J Clin Med. .

Abstract

CD (cluster of differentiation) 69 and CD25 are considered early and late markers of the activation of lymphocytes, respectively. CD25 is a part of the IL-2 receptor and is present on the surface of immune and non-immune cells, with high amounts on activated lymphocytes and regulatory T cells. CD69 is expressed on various types of white blood cells, including newly activated lymphocytes, lymphocytes infiltrating tissues isolated from subjects with chronic auto-inflammatory diseases, several subtypes of memory T cells and regulatory T cells. Primarily, CD69 was considered to be an early marker of the activation of lymphocytes, but, right now, data derived from in vitro and in vivo studies have revealed the immunomodulatory role of this surface antigen. In 84 patients with psoriasis, of whom 28 were treated with different biologic drugs, as well as in 29 healthy control subjects, the expression of CD25 and CD69 on different subtypes of peripheral blood mononuclear cells (PBMCs) was studied with the use of flow cytometry. Significantly higher levels of CD3/CD69-, CD8/CD69- and CD19/CD69-positive PBMCs as well as within CD3+ cells were present in subjects suffering from psoriasis when compared to healthy controls. In patients with psoriasis who were treated with biologic drugs, the levels of CD3/CD69-, CD4/CD69- and CD19/CD69-positive PBMCs, and CD3/CD69 within CD3+ cells, CD4/CD69 within CD4+ cells, CD4/CD25 within CD4+ cells and CD19/CD69 within CD19+ cells were significantly higher than before therapy. Our results support a role for activation markers, especially CD69, in psoriasis. Further research is warranted to fully clarify their significance in this common dermatosis, especially during biologic treatment.

Keywords: activation markers; biologic treatment; psoriasis; systemic treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The gating strategy for flow cytometry evaluation of CD25 and CD69 expression on CD19+ PBMCs in subjects with psoriasis.
Figure 2
Figure 2
The gating strategy for flow cytometry evaluation of CD25 and CD69 expression on CD3+ PBMCs in subjects with psoriasis.
Figure 3
Figure 3
Illustrative flow cytometry assessment of the expression of CD25 (A,C,E,G,I,K,M,O) and CD69 (B,D,F,H,J,L,N,P) in patient with psoriasis (A–H) and healthy control (I–P). Pink color—CD3+ T-cells, blue—CD4+ T-cells, red—CD8+ t-cells and purple—CD19+ cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Armstrong A.W., Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323:1945–1960. doi: 10.1001/jama.2020.4006. - DOI - PubMed
    1. Samotij D., Nedoszytko B., Bartosińska J., Batycka-Baran A., Czajkowski R., Dobrucki I.T., Dobrucki L.W., Górecka-Sokołowska M., Janaszak-Jasienicka A., Krasowska D., et al. Pathogenesis of psoriasis in the “omic” era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances. Postep. Dermatol. Alergol. 2020;37:135–153. doi: 10.5114/ada.2020.94832. - DOI - PMC - PubMed
    1. Jiang Y., Chen Y., Yu Q., Shi Y. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs. 2023;37:35–55. doi: 10.1007/s40259-022-00569-z. - DOI - PMC - PubMed
    1. Peng Y., Tao Y., Zhang Y., Wang J., Yang J., Wang Y. CD25: A potential tumor therapeutic target. Int. J. Cancer. 2023;152:1290–1303. doi: 10.1002/ijc.34281. - DOI - PubMed
    1. Panackel C., Mathew J.F., Fawas N.M., Jacob M. Immunosuppressive Drugs in Liver Transplant: An Insight. J. Clin. Exp. Hepatol. 2022;12:1557–1571. doi: 10.1016/j.jceh.2022.06.007. - DOI - PMC - PubMed